Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that applying an ethanol extract of Prasiola japonica improved hair regrowth, length, and follicular density in testosterone-induced hair loss conditions in mice, while also promoting dermal papilla cell proliferation and reducing dihydrotestosterone production, though effects were less pronounced than those of minoxidil.

This study found that Janus kinase inhibitors significantly improve treatment outcomes for complex skin conditions like atopic dermatitis and alopecia areata, but their implementation requires careful safety considerations, including risk assessments for cardiovascular, malignant, and reproductive issues.

In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.

This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.

In a testosterone-induced mouse model of androgenetic alopecia, this study found that oral and topical administration of Connarus semidecandrus Jack ethanol extract promoted hair regrowth and improved hair health markers similar to finasteride, without detectable liver or kidney toxicity.

This study found that oral JAK inhibitors significantly improve hair regrowth in adults with moderate-to-severe alopecia areata compared to placebo, although they are associated with a higher risk of non-serious adverse events.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

In this study, a herbal hair cream containing natural ingredients like Jamalgota and Amla was developed and evaluated, with Batch 3 showing promising results in texture, pH balance, spreadability, and stability, suggesting it may be a safe and effective option for managing alopecia.

In this study, a herbal hair cream formulated with natural ingredients like Jamalgota and Neem oil was evaluated for managing alopecia; Batch 3 showed the best performance in texture, stability, and spreadability, with promising results as a safe alternative for promoting healthy hair growth.

This study observed that patients with acute alopecia areata treated with Janus kinase inhibitors achieved a higher rate of complete hair regrowth by week 24 compared to those with non-acute disease, highlighting the benefits of early intervention.

In this study, adults with significant alopecia areata were surveyed on their preferences for JAK inhibitor treatments, revealing a strong priority for scalp hair regrowth effectiveness and quicker initial regrowth over dosing convenience.

This review highlights emerging evidence that chemotherapy-induced alopecia may be driven by immune mechanisms similar to alopecia areata, involving hair follicle immune privilege collapse, and evaluates Janus kinase inhibitors as potential treatments, while cautioning about their immunosuppressive risks in cancer patients.

In this study, researchers found that the JAK1/2 inhibitor ruxolitinib helped normalize tissue-specific autoimmunity in APECED patients by reducing inflammation and immune cell accumulation, but it was also linked to subclinical side effects like anemia and weight gain.

This study formulated an herbal anti-dandruff shampoo using jackfruit seed extract and evaluated its effectiveness against Malassezia furfur, finding that the fourth formulation exhibited both strong antifungal activity and stability, suggesting a natural alternative to synthetic hair care products.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This review highlights that JAK inhibitors have transformed severe alopecia areata treatment by disrupting disease signaling, emphasizing the need for strategies to address non-responders and manage treatment discontinuation.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

No results are reported in this dataset abstract, which details supplementary materials for a systematic review and meta-analysis on oral Janus kinase inhibitors' effectiveness and safety in children with alopecia areata, aiming to enhance transparency and interpretation of the main article's findings.

In this systematic review and meta-analysis on participants aged 12 and under with alopecia areata, the authors provide supplementary tables and figures, including pooled outcomes for hair regrowth and safety of oral Janus kinase inhibitors, supporting the main findings on their effectiveness and safety.

This article highlights the rising interest in Janus kinase inhibitors for alopecia areata, especially following the FDA approval of baricitinib, underscoring the need for better patient education and physician guidance in selecting appropriate treatments for hair loss.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

In this study, the bark extract of Albizia saponaria was analyzed for its metabolites and potential anti-alopecia effects, identifying several compounds with predicted affinities for proteins involved in hair loss pathways.

This case series described five patients with chronic alopecia areata who successfully maintained long-term disease control using a combination of topical immunotherapy and other treatments over 9–15 years, highlighting the approach's continued value alongside novel therapies.

Using molecular dynamics simulations, this study explored the uptake processes of JAK inhibitors on stratum corneum and hair follicle membranes, revealing a unique interaction mechanism in the hair follicle and offering insights into transdermal drug delivery pathways.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This study analyzed Reddit discussions on JAK inhibitors and found that a small number of users contribute most of the conversational content, highlighting the need for expert oversight in interpreting health information shared online.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.